The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis

Annals of Hematology

Volumn 95, Issue 9, 2016, Pages 1483-1490

  Liu, Duo ^a   Tian, Yuyang ^a   Sun, Donglin ^a   Sun, Haiming ^a   Jin, Yan ^a   Dong, Mei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

FCGR3A; Meta analysis; Non Hodgkin s lymphoma; Polymorphism; Rituximab

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN;

ALLELE; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; DNA POLYMORPHISM; FCGR3A GENE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RACE DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; GENETICS; LYMPHOMA, NON-HODGKIN; PROGNOSIS; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, IGG; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME;

EID: 84978772067     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2723-x     Document Type: Article

References (43)

1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’ Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126
2. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391
3. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446
4. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290, Review
5. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90(3):1109–1114
6. Liu F, Ding H, Jin X, Ding N, Deng L, He Y, Zhu J, Song Y (2014) FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 33(9):616–623. doi:10.1089/dna.2013.2333
7. Váróczy L, Zilahi E, Gyetvai A, Kajtár B, Gergely L, Sipka S, Illés A (2012) Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res 18(1):43–48. doi:10.1007/s12253-011-9414-7
8. Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G (2012) Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120(13):2650–2657
9. Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, Bendaoud B, Berthou C, Renaudineau Y, Youinou P (2012) Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 91(5):715–721. doi:10.1007/s00277-011-1369-y
10. Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Siedlecki JA (2011) FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 52(8):1604–1606. doi:10.3109/10428194.2011.574760
11. Zhang W, Wang X, Li J, Duan MH, Zhou DB (2010) Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J (Engl) 123(2):198–202
12. Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B (2007) FCgammaR IIIA and FCgammaR IIA polymorphisms are not associated with response to rituximaband CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92(7):998–999
13. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK (2006) FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108(8):2720–2725
14. Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M (2007) The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaR IIIa and FCgammaR IIa polymorphisms. J Chemother 19(3):315–321
15. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR IIIa gene. Blood 99(3):754–758
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 22(4):719–748
19. Burchard PR, Malhotra S, Kaur P, Tsongalis GJ (2013) Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet 206(4):130–134. doi:10.1016/j.cancergen.2013.03.002
20. Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K (2012) High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRIIIa polymorphism. Int Immunol 24(8):477–483. doi:10.1093/intimm/dxs048
21. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118(12):3347–3349. doi:10.1182/blood-2011-05-351411
22. Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G (2012) Model-based design of rituximab dosage optimization in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol 73(4):597–605. doi:10.1111/j.1365-2125.2011.04125.x
23. Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M, Indrak K (2011) FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 58(3):263–270
24. Ternant D, Cartron G, Hénin E, Tod M, Paintaud G, Girard P (2009) Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol 68(4):561–573. doi:10.1111/j.1365-2125.2009.03494.x
25. Weng WK, Levy R (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 50(5):723–727. doi:10.1080/10428190902829441
26. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26(33):5489–5491. doi:10.1200/JCO.2008.19.4118
27. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP (2007) Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 7(4):286–290
28. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110(7):2561–2564
29. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64(13):4664–4669
30. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940–3947
31. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A (2007) FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab. Haematologica 92(8):1127–1130
32. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J (2011) The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 118(17):4657–4662. doi:10.1182/blood-2011-04-346411
33. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97(6):937–942. doi:10.3324/haematol.2011.050419
34. Weng WK, Negrin RS, Lavori P, Horning SJ (2010) Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 28(2):279–284. doi:10.1200/JCO.2009.25.0274
35. Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, Lea RA, Gandhi MK (2012) Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 42(10):1113–1119. doi:10.1111/j.1445-5994.2011.02587.x
36. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, Su YC (2010) Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 85(10):810–812. doi:10.1002/ajh.21818
37. Sarsour K, Greenberg J, Johnston JA, Nelson DR, O’Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G (2013) The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin Exp Rheumatol 31(2):189–194
38. Cartron G (2009) FCGR3A polymorphism story: a new piece of the puzzle. Leuk Lymphoma 50(9):1401–1402. doi:10.1080/10428190903161109
39. Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37–S47, Review
40. Zhuang Y, Xu W, Shen Y, Li J (2010) Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 10(5):347–352. doi:10.3816/CLML.2010.n.067
41. Treon SP (2010) Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(5):321–322. doi:10.3816/CLML.2010.n.063
42. Zhuang Y, Qiao C, Yang G, Shen Y, Qian X, Yang L, Xu W, Li J (2014) FcγRIIIa polymorphisms and efficacy of Rituximab combined chemotherapy for diffuse large B-cell lymphoma in Chinese patients. Zhonghua Xue Ye Xue Za Zhi 35(9):816–821. doi:10.3760/cma.j.issn.0253-2727.2014.09.007
43. Zhang W, Wang X, Duan MH, Li J, Zhou DB (2009) Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study. Zhonghua Yi Xue Za Zhi 89(6):400–402